Cancer Detection: Leadership
Epi One's cancer detection team is managed by an unrivalled blend of individuals with industry-leading cancer-specific scientific expertise and international business experience.
Michael Marquardt
CEO
Michael has led companies in the technology and healthcare sectors and is the Immediate-Past-Chair of the American Cancer Society’s Board of Directors.
As a four-time CEO, corporate board member, and global business advisor, Michael brings deep business experience and global connections to Epi One. Following a lifelong commitment to cancer detection, Michael has served on the national board of the American Cancer Society since 2018 and currently chairs its first enterprise-wide fundraising campaign. He has a Master’s Degree in Chemistry from the University of Virginia.
Sophia F. Fang, MD & PhD
Co-Founder, President & CSO
With both MD and Ph.D. training, Sophia brings a proven record of translating cutting-edge research into clinical success.
Sophia is responsible for scientific strategy, research operations, and growing the company’s scientific team. Prior to co-founding Epi One, Sophia was a senior scientist at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College. Her research was focused on human genomics and translational cancer biology. Sophia has an MD from Harbin Medical University and a Ph.D. in Bioinformatics and Computational Biology from Iowa State University.
Neng Yang, MD & PhD
Co-Founder, Vice President R&D
Neng is an expert in next-generation sequencing technology, immunology, and CAR T-cell immunotherapy.
Neng conducts day-to-day experiments for the cancer detection biomarkers’ clinical validation. Prior to co-founding Epi One she was a research associate at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College. She established a novel single cell sorting and sequencing technology to understand the genetic heterogeneity of leukemia. She also conducted research on CAR T-cell therapy for lung cancer patients. Neng has an MD from Guangdong Medical College and a Ph.D. from ShangHai JiaoTong University.
Daniel Etra
With almost three decades of successful international business experience including over 20 years as a serial entrepreneur, Daniel brings deep industry experience in healthcare and technology, as well as strategy, and operational expertise building and scaling businesses.
Daniel has been Co-Founder and CEO of RethinkFirst, a leading global behavioral health technology company. He was Co-Founder and CEO of R.E.R. International, a global supplier to the retail industry, and a Consultant at Bain & Company. He has an MBA from Harvard Business School and a BA in Economics from Yale University.
MinKui Luo, PhD
Dr. Luo is a full professor at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College. He is interest in discovery research at the interface of chemistry and biology. Specifically, Dr. Luo focuses on studying epigenetic writers (PMTs), readers (Rme/Kme effectors) and erasers (demethylases) with functional relevance to noncanonical histone methylation, protein homeostasis and transcription plasticity
Greg Papaz
Greg is a proven leader in the Biotech and pharmaceutical industry. He has operational success in large multi-national, mid-cap and early-stage, start-up companies. He has expertise in driving commercial business, building start-up organizations, crafting strategic plans for developmental compounds, launching products, raising capital and forging strategic alliances. Piror Newfield Therapeutics Greg was the president and CEO of PAION Inc. (a subsidiary of PAION AG, Germany).